Faeth Therapeutics Adopts Performance-Based Stock Option Plan
I'm LongbridgeAI, I can summarize articles.Faeth Therapeutics (FTH) announced that its board approved one-time performance-based stock option grants under the 2026 Equity Incentive Plan for eligible employees, including CEO Anand Parikh. These options vest only if the stock sustains an average price of $70 over 30 consecutive trading days within four years or achieves equivalent value in a change-of-control transaction; otherwise, they are forfeited. This plan aligns employee incentives with long-term shareholder value.
Faeth Therapeutics ( (FTH) ) has issued an announcement.
On July 21, 2026, Faeth Therapeutics’ board approved one-time performance-based stock option grants under its 2026 Equity Incentive Plan for employees employed as of February 19, 2026, including CEO Anand Parikh and former named executive officers Christopher Gerry and Josiah Craver, who were reclassified as non-executive officers in June 2026. The options carry an exercise price equal to the grant-date Nasdaq closing price and vest only if, within four years and after at least one year of service, the company’s stock sustains an average price of $70 over 30 consecutive trading days or achieves equivalent value in a change-of-control transaction, otherwise they are forfeited, underscoring a strong alignment of employee incentives with shareholder value and long-term share performance.
The performance options vest solely upon Faeth Therapeutics meeting a $70 stock-price hurdle within four years and a one-year service requirement. These grants align leadership and employee compensation more tightly with long-term shareholder returns and potential strategic transactions, while imposing strict forfeiture terms if performance targets are not met.
The most recent analyst rating on (FTH) stock is a Buy
with a $51.00 price target.
To see the full list of analyst forecasts on Faeth Therapeutics stock,
see the FTH Stock Forecast page.
Spark’s Take on FTH Stock
According to Spark, TipRanks’ AI Analyst, FTH is a Neutral.
The score is held down primarily by weak financial fundamentals (no revenue, sustained losses/cash burn, and negative equity in TTM), which heighten financing and dilution risk. Technicals are comparatively supportive (price above key longer-term averages with neutral momentum), but valuation is constrained by ongoing unprofitability and no indicated dividend yield.
To see Spark’s full report on FTH stock,
click here.
More about Faeth Therapeutics
Faeth Therapeutics, Inc. operates in the biopharmaceutical sector, focusing on therapeutic development and related clinical research. The company relies on equity-based incentive plans as part of its compensation strategy to attract and retain key employees in a competitive life sciences talent market.
Average Trading Volume: 116,215
Technical Sentiment Signal: Buy
Current Market Cap: $731.3M
For a thorough assessment of FTH stock, go to TipRanks’ Stock Analysis page.